中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy

文献类型：期刊论文

作者Long, Yiru3,4; Yu, Xiaolu3,4; Chen, Runqiu2,4; Tong, Yongliang3,4; Gong, Likun1,3,4
刊名FRONTIERS IN IMMUNOLOGY
出版日期2022-05-18
卷号13页码:12
关键词noncanonical PD-1 PD-L1 axis T-cells tumor cells myeloid cells anti-PD therapy
ISSN号1664-3224
DOI10.3389/fimmu.2022.910704
通讯作者Gong, Likun(lkgong@simm.ac.cn)
英文摘要With programmed death 1/ligand 1 (PD-1/PD-L1) as the cornerstone, anti-PD antibodies have pioneered revolutionary immunotherapies for malignancies. But most patients struggled to respond to anti-PD owing to primary or acquired resistance or even hyperprogression, pointing to more efforts needed to explore this axis. PD-1 constrains T-cell immunoreactivity via engaging with PD-L1 of tumor/myeloid cells is the canonical PD-1/PD-L1 axis function mode. Studies are increasingly aware of the impact of noncanonical PD-1/PD-L1 expression in various cancers. PD-L1 induced on activated T-cells ligates to PD-1 to mediate self-tolerance or acts on intratumoral myeloid cells and other T-cells, affecting their survival, differentiation and immunophenotyping, leading to tumor immunosuppression. Myeloid PD-1 interferes with their proliferation, differentiation, cytokine secretion and phagocytosis, mediating remarkable pro-tumor effects. Tumor cell intrinsic PD-1 signaling has diverse functions in different tumors, resulting in pro-proliferation or proliferation inhibition. These nonclassical PD-1/PD-L1 functions may be novel anti-PD mechanisms or causes of treatment resistance. This review highlights the nonnegligible role of T-cell-intrinsic PD-L1 and tumor/myeloid PD-1 in the cell interplay network and the complex impact on the efficacy of anti-PD antibodies. Reconsidering and rational utilization of the comprehensive PD-1/PD-L1 axis could cumulate breakthroughs in precision treatment and combination for anti-PD therapies.
WOS关键词CD8 T-CELLS ; DEATH LIGAND 1 ; NK CELLS ; DENDRITIC CELLS ; ANTI-PD-L1 ANTIBODY ; M1 PHENOTYPE ; B7 FAMILY ; B7-H1 ; EXPRESSION ; BLOCKADE
WOS研究方向Immunology
语种英语
WOS记录号WOS:000805003400001
出版者FRONTIERS MEDIA SA
源URL[http://119.78.100.183/handle/2S10ELR8/301301]  
专题新药研究国家重点实验室
通讯作者Gong, Likun
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Zhongshan Inst Drug Discovery, Zhongshan, Peoples R China
2.Shenyang Pharmaceut Univ, Wuya Coll Innovat, Dept Pharmaceut, Shenyang, Peoples R China
3.Univ Chinese Acad Sci, Beijing, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
推荐引用方式
GB/T 7714		 Long, Yiru,Yu, Xiaolu,Chen, Runqiu,et al. Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy[J]. FRONTIERS IN IMMUNOLOGY,2022,13:12.
APA Long, Yiru,Yu, Xiaolu,Chen, Runqiu,Tong, Yongliang,&Gong, Likun.(2022).Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.FRONTIERS IN IMMUNOLOGY,13,12.
MLA Long, Yiru,et al."Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy".FRONTIERS IN IMMUNOLOGY 13(2022):12.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。